On January 5, 2026 Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, reported that it will present at the 44th annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kathy Dong, PharmD, MBA, President and CEO of Electra Therapeutics, will present an overview of the company and its portfolio of first-in-class SIRP-targeted therapies.
Presentation Details:
Date: Tuesday, January 13, 2026
Time: 2:30 p.m. PT
Location: The Westin St. Francis
Electra is advancing ELA026 as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory disease, in the SURPASS Phase 2/3 pivotal study across the U.S. and Europe. The company is also expanding ELA026 into hematologic cancers and advancing its second pipeline program, ELA822, toward the clinic for diseases in immunology and inflammation (I&I).
(Press release, Electra Therapeutics, JAN 5, 2026, View Source [SID1234661714])